Fluence, a leader in psychedelic therapy education, has partnered with Compass Pathways to develop a certificate program preparing clinicians to support patients receiving COMP360, a synthetic psilocybin treatment for treatment-resistant depression, pending FDA approval. The program includes three modules covering psychedelic care foundations, psilocybin understanding, and COMP360-specific training. This initiative aims to ensure clinicians are equipped with the skills and knowledge to safely administer and manage COMP360 treatment, aligning with clinical research and regulatory standards. The program also supports healthcare organizations in workforce training and credentialing.
Flip Electronics has signed an authorized distribution agreement with Littelfuse to supply a wide range of Littelfuse's end-of-life, obsolete, aged, and excess electronic components. This partnership aims to support industries like industrial, milita...
Purepoint Uranium Group reported strong assay results from its 2026 winter drilling at the Nova Target, part of the Dorado Joint Venture with IsoEnergy. The highlight was a high-grade uranium intercept of 1.65% U₃O₈ over 0.3 metres at 390.4 metres de...
Apple shares recently dropped nearly 3%, prompting one investor to buy more, viewing the dip as a chance to invest in Apple's unique dual business model. Apple excels by selling popular hardware like iPhones and then generating high-margin recurring ...
Bitcoin ETFs like BlackRock's IBIT provide investors with price exposure to Bitcoin through traditional brokerage accounts without requiring direct ownership or self-custody of the cryptocurrency. ETFs charge annual management fees and trade during s...
Marubeni Corporation is recommended as a buy due to its efforts to improve returns on invested capital (ROIC) and reduce its weighted average cost of capital (WACC). The company is focusing on high-ROIC strategic businesses and applying stricter eval...
